Humacyte, Inc. (HUMA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.60+1.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Maintain Nasdaq listing by meeting minimum bid price: last close $0.60 vs Nasdaq $1.00 threshold.
Humacyte expands strategic partnerships, like the VA hospital contract. The company raised $50 million in a public offering to improve financial stability. Analysts expect revenue to grow from $6.3 million in 2026 to $26.3 million in 2027. Management is addressing Nasdaq listing compliance to maintain its listing.
Humacyte is loss-making with a negative EPS of -$0.35 expected in 2026. The stock fell 48% from its high and recently sold off 3.5% in five days. The public offering dilutes shares and raises concerns about financial stability. Nasdaq delisting risk remains due to minimum bid price issues.
The market prices in a turnaround with implied growth of 38% over five years but also reflects elevated risk and loss-making status. Our fair value of $0.15 matches consensus but the recent 48% drawdown signals skepticism about near-term recovery.
Breaks if: Fails to maintain minimum bid price required by Nasdaq
Breaks if: Fails to secure capital or liquidity runs critically low
Breaks if: Revenue growth falls below $6 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity within the healthcare sector. The current thesis state is cautious due to recent performance issues and regulatory challenges.
The market appears to be pricing in a fragile situation, with high expectations for future growth despite the current losses. HUMA's valuation is expensive compared to peers, reflecting the optionality in its business model.
Fundamentals are likely to remain under pressure in the near term, especially given the recent earnings miss and ongoing regulatory issues. Management's focus on commercialization and partnerships shows some progress, but the mixed results indicate uncertainty.
The long-term thesis hinges on the performance of sector bellwethers and HUMA's ability to advance its commercialization efforts. Additionally, any further deterioration in the jobs market could negatively impact HUMA's performance.
In the next 1-3 years, HUMA's outlook will depend heavily on its management execution and external sector conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company advanced regulatory filings for Symvess and ATEV. This supports its commercialization goals. However, the latest earnings report showed a significant miss. This miss raises concerns about future performance.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.